TY  - JOUR
T1  - COst-effectiveness of respiratory syncytial virus prophylaxis in various indications
AU  - Hampp C, Kauf TL, Saidi AS, Winterstein AG
Y1  - 2011/06/01
N1  - 10.1001/archpediatrics.2010.298
JO  - Archives of Pediatrics & Adolescent Medicine
SP  - 498
EP  - 505
VL  - 165
IS  - 6
N2  - 
Respiratory syncytial virus (RSV) infections are the most common cause of hospitalization in early childhood, accounting for 57 000 to 120 000 hospitalizations each year in the United States.1- 2 Immunoprophylaxis for RSV infection is limited by the high cost of the prophylactic agent, palivizumab (Synagis; MedImmune, Inc, Gaithersburg, Maryland). Dosed at 15 mg/kg body weight, one 50-mg vial is necessary to immunize a newborn child (3 kg) for 1 month at an average wholesale price (AWP) of $1145.47.3 Depending on a child's underlying risk, the American Academy of Pediatrics recommends prophylaxis during 5 months of the RSV season for children up to 2 years of age.4 With increasing body weight, older children require higher doses of palivizumab. Consequently, the cost of prophylaxis for a child in the second year of life (>10 kg) can exceed $3000 per month or $15 000 per RSV season, amplifying the financial burden of prophylaxis against RSV infection.

SN  - 1072-4710
M3  - doi: 10.1001/archpediatrics.2010.298
UR  - http://dx.doi.org/10.1001/archpediatrics.2010.298
ER  -